echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 1990;322(22):1561–1566 212 Madueme PC, Khoury PR, Urbina EM, Kimball TR Predictors of exaggerated exercise-induced systolic blood pressures in young patients after coarctation repair Cardiol Young 2012;1–7 213 Gidding SS, Rocchini AP, Moorehead C, Schork MA, Rosenthal A Increased forearm vascular reactivity in patients with hypertension after repair of coarctation Circulation 1985;71(3):495–499 214 Beekman RH, Katz BP, Moorehead-Steffens C, Rocchini AP Altered baroreceptor function in children with systolic hypertension after coarctation repair Am J Cardiol 1983;52(1):112–117 215 Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report2000 J Heart Lung Transplant 2000;19(10):909–931 216 Johnson DE, Gao SZ, Schroeder JS, DeCampli WM, Billingham ME The spectrum of coronary artery pathologic findings in human cardiac allografts J Heart Transplant 1989;8(5):349– 359 217 Benza RL, Zoghbi GJ, Tallaj J, et al Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience J Am Coll Cardiol 2004;43(11):1973–1981 218 Winters GL, Kendall TJ, Radio SJ, et al Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts J Heart Transplant 1990;9(4):364–371 219 Baker AM, Levine TB, Goldberg AD, Levine AB Natural history and predictors of obesity after orthotopic heart transplantation J Heart Lung Transplant 1992;11(6):1156–1159 220 Wenke K, Meiser B, Thiery J, et al Simvastatin initiated early after heart transplantation: 8-year prospective experience Circulation 2003;107(1):93–97 221 Mahle WT, Vincent RN, Berg AM, Kanter KR Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation J Heart Lung Transplant 2005;24(1):63–66 222 Valantine H Cardiac allograft vasculopathy after heart transplantation: risk factors and management J Heart Lung Transplant 2004;23(5 suppl):S187–S193 223 Tsuda E, Kamiya T, Ono Y, et al Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diameter during Kawasaki disease Pediatr Cardiol 2005;26(1):73–79 224 Orenstein JM, Shulman ST, Fox LM, et al Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study PLoS ONE 2012;7(6):e38998 225 McCrindle BW, Rowley AH, Newburger JW, et al Diagnosis, Treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association Circulation 2017;135(17):e927–e999 226 Rhodes J, Curran TJ, Camil L, et al Sustained effects of cardiac rehabilitation in children with serious congenital heart disease Pediatrics 2006;118(3):e586–e593 227 Rhodes J, Curran TJ, Camil L, et al Impact of cardiac rehabilitation on the exercise function of children with serious congenital heart disease Pediatrics 2005;116(6):1339–1345 228 Iemura M, Ishii M, Sugimura T, Akagi T, Kato H Long term consequences of regressed coronary aneurysms after Kawasaki disease: ... serious congenital heart disease Pediatrics 2006;118(3):e586–e593 227 Rhodes J, Curran TJ, Camil L, et al Impact of cardiac rehabilitation on the exercise function of children with serious congenital heart disease Pediatrics... Mahle WT, Vincent RN, Berg AM, Kanter KR Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation J Heart Lung Transplant 2005;24(1):63–66 222 Valantine H Cardiac allograft vasculopathy after